Cerebral Glucose Metabolism Assessment in Huntington's Disease
Data Collection
Basal Ganglia Diseases+19
+ Brain Diseases
+ Central Nervous System Diseases
Summary
Study start date: August 1, 1993
Actual date on which the first participant was enrolled.PROTOCOL OUTLINE: Participants are screened for Huntington's disease, including cerebral glucose metabolism assessment and genetic testing. Studies include a detailed family history and neurologic, psychometric, and neurobehavioral evaluations. Imaging includes positron emission tomography with fluorodeoxyglucose and brain magnetic resonance imaging. A genotype assessment is performed; genetic results are not disclosed to patients or relatives.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.90 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Healthy volunteers allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Documented family history of Huntington's disease (HD) Symptomatic HD: chorea required At-risk for HD: no detectable systemic or oculomotor abnormality Age-matched control subjects No history of inherited neurological disease No general or neurologic abnormality --Prior/Concurrent Therapy-- At least 4 weeks since other HD treatment, e.g.: Haloperidol Benzodiazepine Other tranquilizers or neuroleptics --Patient Characteristics-- No pregnant women